Rapport Therapeutics Advances RAP-219 into Phase 3, Secures China Deal
Event summary
- RAP-219 Phase 2a trial in focal onset seizures (FOS) met primary endpoints with 77.8% median reduction in clinical seizure frequency.
- Phase 3 trial for RAP-219 in FOS expected to begin in Q2 2026, accelerated from previous Q3 guidance.
- Strategic collaboration with Tenacia Biotechnology for Greater China rights to RAP-219, including $20M upfront and $308M in potential milestones.
- Company ended 2025 with $490.5M in cash, sufficient to fund operations into 2H 2029.
The big picture
Rapport Therapeutics is positioning RAP-219 as a potential best-in-class treatment for epilepsy, leveraging strong Phase 2a data to accelerate its Phase 3 program. The China deal with Tenacia Biotechnology expands its commercial reach, while its robust cash position provides runway for multiple pipeline initiatives. The company's precision neuroscience approach aims to address significant unmet needs in neurological and psychiatric disorders, competing in a market where targeted therapies are increasingly valued.
What we're watching
- Regulatory Momentum
- Whether the accelerated Phase 3 timeline for RAP-219 in FOS can be maintained following the FDA meeting.
- Commercial Expansion
- The pace at which Tenacia Biotechnology can integrate RAP-219 into its Greater China strategy.
- Pipeline Diversification
- How Rapport Therapeutics balances its focus on epilepsy with progress in bipolar mania and chronic pain programs.
Related topics